We are live on ! Find out more
STRO icon

Sutro Biopharma

138 hedge funds and large institutions have $1.01B invested in Sutro Biopharma in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 31 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

348% more call options, than puts

Call options by funds: $6.06M | Put options by funds: $1.35M

103% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 31

23% more capital invested

Capital invested by funds: $819M → $1.01B (+$191M)

20% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 20

3% more funds holding

Funds holding: 134138 (+4)

1.01% more ownership

Funds ownership: 8.66%9.67% (+1%)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
138
Holders Change
+4
Holders Change %
+2.99%
% of All Funds
2.42%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.07%
New
24
Increased
63
Reduced
31
Closed
20
Calls
$6.06M
Puts
$1.35M
Net Calls
+$4.71M
Net Calls Change
+$3.98M
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
51
Wells Fargo
California
$3.27M +$1.92M +8,099 +129%
KCM
52
Kennedy Capital Management
Missouri
$3.22M -$213K -899 -6%
IBT
53
International Biotechnology Trust
United Kingdom
$3.17M
Rafferty Asset Management
54
Rafferty Asset Management
New York
$3.13M +$3.26M +13,730 New
IC
55
Ikarian Capital
Texas
$3.08M -$11.4M -48,000 -78%
Two Sigma Investments
56
Two Sigma Investments
New York
$2.7M +$1.65M +6,966 +143%
Deutsche Bank
57
Deutsche Bank
Germany
$2.66M -$1.9K -8 -0.1%
Jacobs Levy Equity Management
58
Jacobs Levy Equity Management
New Jersey
$2.43M -$1.2M -5,072 -32%
Bank of New York Mellon
59
Bank of New York Mellon
New York
$2.31M +$13.8K +58 +0.6%
AllianceBernstein
60
AllianceBernstein
Tennessee
$2.02M +$1.73M +7,292 +459%
DCM
61
DAFNA Capital Management
California
$1.94M
Charles Schwab
62
Charles Schwab
California
$1.85M +$265K +1,117 +16%
AAA
63
Affinity Asset Advisors
New York
$1.82M -$2.85M -12,000 -60%
EGI
64
EAM Global Investors
California
$1.69M -$1.11M -4,665 -39%
Goldman Sachs
65
Goldman Sachs
New York
$1.67M -$1.41M -5,948 -45%
SSA
66
Schonfeld Strategic Advisors
New York
$1.63M -$1.56M -6,562 -48%
PAM
67
Panagora Asset Management
Massachusetts
$1.53M +$43.2K +182 +3%
Susquehanna International Group
68
Susquehanna International Group
Pennsylvania
$1.51M +$1.58M +6,658 New
Two Sigma Advisers
69
Two Sigma Advisers
New York
$1.36M +$401K +1,690 +39%
JP Morgan Chase
70
JP Morgan Chase
New York
$1.34M -$178K -751 -11%
Russell Investments Group
71
Russell Investments Group
United Kingdom
$1.26M +$102K +430 +8%
California Public Employees Retirement System
72
California Public Employees Retirement System
California
$1.2M -$30.8K -130 -2%
EI
73
EAM Investors
California
$1.2M -$780K -3,289 -38%
SFI
74
Susquehanna Fundamental Investments
Pennsylvania
$1.16M -$301K -1,270 -20%
California State Teachers Retirement System (CalSTRS)
75
California State Teachers Retirement System (CalSTRS)
California
$1.12M +$162K +684 +16%

STRO Hedge Fund Activity: Q1 2021 in Review

138 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2021, worth a combined $1.01B — up 23% from $819M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new STRO positions and 20 closed out — a net gain of 4 holders — while 63 added to existing stakes and 31 trimmed.

The largest buyer was State Street, adding an estimated $48.9M. The largest seller was BVF Inc, cutting an estimated $24.4M.

  • 138 institutional investors held Sutro Biopharma (STRO) as of Q1 2021, up from 134 in Q4 2020.
  • Funds reported $1.01B of Sutro Biopharma stock for Q1 2021, up 23% quarter-over-quarter.
  • 24 funds opened new Sutro Biopharma positions in Q1 2021 and 20 closed out, a net change of +4 holders.
  • The largest Sutro Biopharma buyer in Q1 2021 was State Street, an estimated $48.9M added.
  • The largest Sutro Biopharma seller in Q1 2021 was BVF Inc, an estimated $24.4M sold.

Based on aggregated 13F filings for Q1 2021.